ID   PC-9/S2
AC   CVCL_T016
SY   PC-9S2
DR   cancercelllines; CVCL_T016
DR   Cosmic; 2015226
DR   Wikidata; Q54938503
RX   PubMed=23733853;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=23733853; DOI=10.1101/gr.152322.112;
RA   Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L.,
RA   Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.;
RT   "Next-generation sequencing of paired tyrosine kinase
RT   inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines
RT   identifies spectrum of DNA changes associated with drug resistance.";
RL   Genome Res. 23:1434-1445(2013).
//